SecBot SecBot

ALZN

Alzamend Neuro, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001677077 Biotech & Drug Discovery
$1.13 +0.01 (+0.89%)
Oct 23 4:00 PM ET · prev $1.12
Market cap
$5.4M
Nano cap
Consensus
Buy
86% Buy or better · 7 analysts
Median target
$26.00
+2201% · range $26.00–26.00
1 year
−53.9%
from $2.45 · Oct 27
30 days
−34.7%
from $1.73
52-week range
$0.8580–2.61
−57% from high · low Apr 10
Avg volume 20D
40.0K
Oct 2 spike 236.4K
Short interest
🔒 Subscribers only
Insider net
+$107.8K
1 buyer · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2
Strongest NEUTRAL Alzamend Neuro filed an 8-K to disclose a presentation at the ISMRT Conference on September 29, 2026, by the…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • B Apr 14 1 insider buy $111.0K at $1.01
  • X Jul 31 Short interest falls 28.0% to 236.4K
  • X Aug 14 Short interest falls 25.3% to 176.6K
  • S Aug 26 1 insider sell $3.1K at $1.56

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $111.0K at an average $1.01. 1 insider sold $3.1K. Price is 12% above their cost.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    6 of 7 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.660 → −$0.230 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    28% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM26,371$31.6K
VANGUARD CAPITAL MANAGEMENT LLCADD7,556$9.1K
UBS Group AGTRIM2,352$2.8K
GEODE CAPITAL MANAGEMENT, LLCADD45,680$48.4K
UBS Group AGNEAR_EXIT4,504$4.8K
GEODE CAPITAL MANAGEMENT, LLCADD27,506$50.1K
UBS Group AGDOUBLED24,567$44.7K
UBS Group AGDOUBLED2,075$4.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 86% rate it Buy or better
Strong Buy2Buy4Hold1Sell0Strong Sell0
12-month targets · 1 analysts

Price is below the lowest target. Median implies +2201%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Aug 19, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$111.0K
bought · 1 insider
$3.1K
sold · 1 insider
+12.4%
vs their $1.01 cost
DateInsiderTypeValue
Aug 26, 2026
AULT MILTON C III
Director
SELL$3.1K
Jul 31, 2026
Hyperscale Data, Inc.
Director
AWARD$7.5M
Jul 31, 2026
AULT MILTON C III
Director
AWARD$7.5M
Apr 14, 2026
AULT MILTON C III
Director
BUY$108.9K
Apr 14, 2026
AULT MILTON C III
Director
BUY$2.1K

Earnings setup

Estimates
−$0.23
EPS estimate, this quarter
+65%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.23-$0.23–-$0.23+65.2%$0.00
Next Q-$0.22-$0.22–-$0.22+65.6%$0.00
Current FY-$1.05-$1.05–-$1.05+59.6%$0.00
Next FY-$0.87-$0.87–-$0.87—$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 SEC
Alzamend Neuro filed an 8-K to disclose a presentation at the ISMRT Conference on September 29, 2026, by the principal…
8-K — Impact 3/10
Sep 16, 2026 Other
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
ATLANTA, Sept. 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical
Aug 26, 2026 Insider
AULT MILTON C III sold 2,000 shares
Director @ $1.56 ($3.1K)
Aug 4, 2026 SEC
Hyperscale Data, Inc. (HSD) filed a Form 3 initial statement of beneficial ownership for Alzamend Neuro (ALZN)…
3 — Impact 2/10
Jul 31, 2026 Insider
Hyperscale Data, Inc. was granted 7,500 shares
Director @ $1,000.00 ($7.5M)
Jul 31, 2026 Insider
AULT MILTON C III was granted 7,500 shares
Director @ $1,000.00 ($7.5M)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
26,371 shares ($31.6K)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
7,556 shares ($9.1K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 16, 2026
Press release
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
ATLANTA, Sept. 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on…
Sep 8, 2026
Earnings date
ALZN Q1 2027 Earnings Scheduled — 2026-09-08
Jul 20, 2026
Earnings date
ALZN Q4 2026 Earnings Before Market Open — 2026-07-20
Mar 9, 2026
Earnings date
ALZN Q3 2026 Earnings Scheduled — 2026-03-09

SecBot reports

3 filings · 0 bullish · 0 bearish · 3 neutral
All ALZN filing & press-release reports (3)